Trans-Atlantic VC banks $126M to scout startup ideas out of 'underventured' areas in the UK
The global glut in biotech venture dollars is fattening more than just the traditional hubs — at least Epidarex Capital hopes. The trans-Atlantic fund also has $126 million (£102.1 million) to prove it.
Sinclair Dunlop and Kyp Sirinakis, the co-managing partners, planted their US headquarters just outside of the NIH in Bethesda, MD 10 years ago in a direct shoutout to the focus on “underventured” areas. For this third, UK-focused fund, the thesis remains the same: to bring scalable specialist life sciences capital to regions where not that many VCs are willing to go, at least for seed or Series A deals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
